en | es | val
en · es · val

Clinical Trials

ivo.es Research Clinical Trials

What is a clinical trial?

A study to determine whether a new treatment, drug, device, or diagnostic or therapeutic technique will help prevent, detect or treat a disease by being applied to humans.

Clinical trials also help to find out whether or not these new treatments are safe and whether they are better than treatments that are currently available.

The entire process for the commercialisation of a new medicine takes about 10 years. During that time, the number of subjects/trials gradually increases.

Phases of a clinical trial

The development of new drugs goes through a process called clinical trials: research aimed at finding new drugs for the prevention and treatment of diseases, including cancer, as well as new diagnostic and surgical techniques.

After the pre-clinical phase (in order to obtain new chemical substances and experimenting with animals in the laboratory) and before marketing the drug, researchers test its efficacy, check its safety and analyse its results in comparison with those of previously available drugs.

Trials that compare the treatment under investigation with the established therapy are called “double-blind”. Neither the participants nor the researchers know who is receiving which treatment. This ensures objectivity.

Tolerance and safety

This is the first step in human drug research. It is usually done on healthy volunteers, or patients when it comes to anti-cancer drugs, i.e. drugs that prevent or slow down cell division and are used in the treatment of cancer. They give us preliminary information on the safety and tolerability of these drugs.

Comparison of efficacy and safety with standard treatments

The sample size is extended to thousands of patients. Numerous researchers are involved to assess the efficacy of the new medicine. Adverse effects are analysed. The new drug is compared with standard treatment to confirm evidence of efficacy. This phase takes place prior to the authorisation and marketing of a drug.

Marketing and new indications

The drug is already on the market. Testing is carried out to monitor the long-term safety of the medicine and to analyse the results on the disease itself. New indications or dosages of the product are studied and compared with other known medicines.

Clinical trials carried out by the IVO

Description of clinical trials by speciality and tumour.

TITLE: Hemopatch Versus Axillary Drainage After Axillary Lymphadenectomy: Randomized, Controlled, Multicenter Clinical Study. CODE: REDHEMOPACH 


TITLE: Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Mytomicin-C After Complete Surgical Cytoreduction in Patients With Colon Cancer Peritoneal Metastases. CODE: GECOP-MMC

TITLE:A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX).
CODE: Debio 1143-SCCHN-301 (TrilynX_)

TITLE: A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma.
CODE: R2810-ONC-1788


TITLE: A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers (only cohort 7 open: Histologically confirmed diagnosis of unresectable or metastatic cutaneous squamous cell carcinoma (cSCC) not amenable to local therapy).
CODE: CK-301-101

TITLE: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma


TITLE: Phase II Study of Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (The DUREC Trial)
CODE: ESR-17-13082 GEMCAD 17-03 (DUREC)

TITLE: A Randomized, Open Label, Phase II Trial of Anti-PD1, TSR-042, as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation.


TITLE: Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial


TITLE: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer.
CODE: VB-111-701/GOG-3018 (OVAL)


TITLE: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma.


TITLE:A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15). CODE: MK-3475-C93/GOG-3064/ENGOT-en15


TITLE: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: a randomised phase III study. CODE: SSGXXII (GEIS 42)


TITLE: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC). CODE: AVB500-OC-004/ GOG-3059/ ENGOT OV66

TITLE: A window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer. CODE: AWARE-1

TITLE: Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study). CODE: MedOPP107-­ PHENOMENAL

TITLE: A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer. CODE: IBCSG 59-19 / BIG 18-02 (POLAR)

TITLE: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer. CODE: WO39391.- IMpassion 030 (BIG 16-05/AFT-27)

TITLE: A Phase II Study of Adjuvant PALbociclib as an Alternative to Chemotherapy in Elderly patients With High-risk ER+/HER2- Early Breast Cancer. CODE: EORTC-1745-ETF-BCG (APPALACHES)

TITLE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer. CODE: WO41554

TITLE: Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer. CODE: SOLTI-1502 (ARIANNA)

TITLE: A Phase Ib Study of Ipatasertib, an AKT Inhibitor, in Combination With Pertuzumab Plus Trastuzumab in Patients With PI3KCA-mutant, HER2-positive Locally Advanced or Metastatic Breast Cancer. CODE: SOLTI-1507 (IPATHER)

TITLE: Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment. CODE: SOLTI-1716 (TATEN)

TITLE: Multicenter,Open-label,Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib + Aromatase Inhibitors for(HR)+/(HER2)-, MBC With Either Germline BRCA-mutated or Germinal BRCA-wildtype and Homologous Recombination Deficiency. CODE: MedOPP190 (LUZERN)

TITLE: Phase II, Randomized, Open-label, International, Multicenter Study to Compare Efficacy of Standard Chemotherapy vs. Letrozole Plus Abemaciclib as Neoadjuvant Therapy in HR-positive/HER2-negative High/Intermediate Risk Breast Cancer Patients. CODE: GEICAM/2019-01-CARABELA

TITLE: A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor. CODE: D3615C00001 (CAPItello-291).

TITLE: Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 HER2+ Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis. CODE: MedOPP243 (DEBBRAH)

TITLE: Study to Evaluate the Effect of Metformin in the Prevention of Hyperglycemia in HR[+]/HER2[-] PIK3CA-mutation Advanced Breast Cancer Patients Treated With Alpelisib Plus Endocrine Therapy. Study Metallica. CODE: MedOPP240 METALLICA

TITLE: HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a). CODE: SOLTI-1804 (Her2Predict)

TITLE: An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib. CODE: UC-0140/1812 (DOLAF)

TITLE: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with her2-positive early breast cancer. CODE: ML 42502 (PHATIMA)

TITLE: Eficacia de spartalizumab en múltiples tipos de cáncer en pacientes con tumores con expresión elevada de ARNm de PD1, definida según un punto de corte preespecificado. CODE: SOLTI-1904 (ACROPOLI)

TITLE: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05). CODE: DS8201-A-U305 (DESTINY-Breast05)

TITLE: Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2). CODE: MedOPP293_PHERGAIN-2

TITLE: A randomized, double-blind, placebo-controlled, Phase III study of Pembrolizumab plus chemotherapy versus Placebo plus chemotherapy for the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast. CODE: MK3475-B49

TITLE: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers. CODE: J2J-MC-JZLA

TITLE: A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study". CODE: CAN04CLIN005

TITLE: An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12). CODE: D9673C00007 (DESTINY-Breast12)

TITLE: A phase II, randomised study to evaluate the incidence of discontinuation due to diarrhoea in the first three treatment cycles in patients with early HER2-positive, hormone receptor-positive breast cancer treated with Neratinib plus Loperamide versus Neratinib with initial dose escalation plus Loperamide (as needed) versus Neratinib plus Loperamide plus Colesevelam. CODE: GEICAM/2018-06_DIANER

TITLE: Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-risk Estrogen Receptor-positive (ER+) and HER2-negative (HER2-) Breast Cancer. CODE: SOLTI-1911 (RIBOLARIS)

TITLE: A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma. CODE: CA209-76K.


TITLE: A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M With or Without Stereotactic Body Radiation in Adults With Unresectable or Metastatic Melanoma. CODE: APX005M-010

TITLE: TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency. CODE: CO-338-063 (TRITON 3)

TITLE: A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641). CODE: MK-3475-641

TITLE: A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer. CODE: MEDOPP234 (ZZ-First Study).

TITLE: A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel antihormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH. CODE: BAY 88-8223 / 20510

TITLE: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer. CODE: CAAA617B12302

TITLE: A Phase II, Open-Label, Biomarker-Guided Study of Carboplatin Efficacy in Pretreated Metastatic Castration-Resistant Prostate Cancer (mCRPC)-BioChiP. CODE: BioChip (CNIO-CP-2019-01).

TITLE:A Phase 3, Randomized, Double-Blind, Study of Talazoparib with Enzalutamide versus Placebo with Enzalutamide in Men With DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer. CODE: C3441052 _ TALAPRO-3.

TITLE:A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer. CODE: SHR3162-III-305 (FUZUPRO)

TITLE: A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy. CODE: HR-BLTN-III-NSCLC _ PYR301


TITLE: A Phase III Clinical Trial of Adjuvant Chemotherapy vs Chemo-Immunotherapy for Stage Ib-IIIa Completely Resected Non-Small Cell Lung Cancer (NSCLC) Patients. CODE: NADIM (CA209-7YC)-GECP 20/05


TITLE: A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE. CODE: 516-005 (MIRATI)

TITLE: Phase II Study of Cabozantinib Tolerability, SAFETY and EFFICACY in Metastatic Renal Carcinoma in Aged Fragile Patients (CABOMAYOR). CODE: SOGUG-2018-A-IEC (REN)-2 (CABOMAYOR)

TITLE: A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk. CODE: EXELISIS (XL184-313) (COSMIC)

TITLE: An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies. CODE: MK-6482-005.

TITLE: A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61). CODE: MK-3475-B61

TITLE: A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma. CODE: D7980C00003 (MEDI5752).

TITLE An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. CODE: SGN22e-003 (EV-302).

TITLE: A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3). CODE: G1T28-209 PRESERVE 3 (PXL 258576)

TITLE: Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. CODE: GEIS 51

TITLE: A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial. CODE: GETNE T1812 (DUTHY)

TITLE: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors. CODE: 4010-01-001 (TSR-042) GARNET


TITLE: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. CODE: Apollomics (APL-101-01).


TITLE: A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1). CODE: TPX-0005-01 (TRIDENT-1).


TITLE: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. CODE: MK3475-587.


TITLE: A Phase 2 Study of Futibatinib in Patients With Specific FGFR Aberrations. CODE: TAS-120-202.


TITLE:A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation. CODE:JAB-21822-1001

TITLE: A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects With Metastatic or Locally Advanced Urothelial Cancer. CODE: 42756493BLC2002 (NORSE).

TITLE: A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chemotherapy. CODE: NICARAGUA (FCR173009)

TITLE: A randomized phase II trial assessing trimodality therapy with or without adjuvant Durvalumab (MEDI4736) to treat patients with muscle-invasive bladder cáncer. CODE: BL.13.

TITLE: A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer. CODE: CA209-901

TITLE: A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866). CODE: MK-3475-866

TITLE: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302). CODE: QBGJ398-302 (PROOF 302)

TITLE: A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy. CODE: BO42843 (IMVigor011)

TITLE: A Phase 2 Randomized Open-Label Study of Oral Darolutamide (ODM-201) vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer. CODE: EORTC 1532


TITLE: A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303). CODE: MK-3475-905.


TITLE: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy. CODE: 56021927PCR3011 (PROTEUS).


TITLE: Phase II Safety and Efficacy of Personalized Lymphadenectomy or Guided by Indocyanine Green (IGC) vs Extended Pelvic Lymph Node Dissection in Patients Diagnosed with Prostate Cancer Subsidiaries of Radical Prostatectomy and Lymphadenectomy. CODE: PersonaLymPCA.


TITLE: A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions. CODE: 42756493BLC2003 (RAGNAR-THOR-2)


TITLE: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC. CODE: B8011006


TITLE: A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer or PF-06801591 as a Single Agent in Participants With BCG-Unresponsive NMIBC . CODE: HC1119-CS-03


TITLE: Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial ("URANUS"). CODE: URANUS

How to participate

Patients always sign an informed consent form stating that they agree to participate in the trial and that they have been given all the relevant information.

Patients are free to decide whether or not to participate in a clinical trial; they may only join one and they can leave at any time if they wish.

Clinical trials are regulated by law and require the approval of both the hospital’s Board and the Ethics Committee.

Scientific studies

These are research projects that aim to evaluate a certain aspect or factor of a drug that affects the treatment of a group of patients.

The aim of these studies is to answer questions after observing the effects of authorised drugs or standard treatments in patients, taking into account their genetic characteristics.